Results 21 to 30 of about 35,703 (223)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

Journal of Lipid Research, 2014
Secreted PCSK9 binds to cell surface LDL receptor (LDLR) and directs the receptor for lysosomal degradation. PCSK9 is potent at inducing LDLR degradation in cultured liver-derived cells, but it is considerably less active in immortalized fibroblasts.
My-Anh Nguyen, Tanja Kosenko, Thomas A. Lagace   +2 more
doaj   +1 more source

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Biomolecules, 2022
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms.
Arianna Toscano, Maria Cinquegrani, Michele Scuruchi, Antonino Di Pino, Salvatore Piro, Viviana Ferrara, Carmela Morace, Alberto Lo Gullo, Egidio Imbalzano, Francesco Purrello, Giovanni Squadrito, Roberto Scicali, Giuseppe Mandraffino   +12 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G

JCI Insight, 2022
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses.
Alexander Merleev, Antonio Ji-Xu, Atrin Toussi, Lam C. Tsoi, Stephanie T. Le, Guillaume Luxardi, Xianying Xing, Rachael Wasikowski, William Liakos, Marie-Charlotte Brüggen, James T. Elder, Iannis E. Adamopoulos, Yoshihiro Izumiya, Annie R. Leal, Qinyuan Li, Nikolay Y. Kuzminykh, Amanda Kirane, Alina I. Marusina, Johann E. Gudjonsson, Emanual Maverakis   +19 more
doaj   +1 more source

Polymorphic Variant rs11206510 in PCSK9 and Risk of Coronary Artery Disease in Bulgarians

Acta Medica Bulgarica, 2023
The aim of this study was to investigate the potential association of rs11206510 in PCSK9 gene with coronary artery disease (CAD) and myocardial infarction (MI) in Bulgarians.
Tzveova R., Yaneva-Sirakova T., Naydenova G., Vandeva S., Pendicheva-Duhlenska D., Atanasov P., Mitev V., Kaneva R.   +7 more
doaj   +1 more source

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome

Frontiers in Medicine, 2022
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells.
Thomas S. Metkus, Bo Soo Kim, Steven R. Jones, Seth S. Martin, Steven P. Schulman, Thorsten M. Leucker   +5 more
doaj   +1 more source

Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism [PDF]

, 2017
No abstract ...
Packard, Chris J.
core   +1 more source

Naturally Occurring PCSK9 Inhibitors [PDF]

Nutrients, 2020
Genetic, epidemiological and pharmacological data have led to the conclusion that antagonizing or inhibiting Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces cardiovascular events. This clinical outcome is mainly related to the pivotal role of PCSK9 in controlling low-density lipoprotein (LDL) cholesterol levels.
Maria Pia Adorni, Francesca Zimetti, Maria Giovanna Lupo, Massimiliano Ruscica, Nicola Ferri   +4 more
openaire   +5 more sources

Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome

Renal Failure, 2020
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a major post-transcriptional regulator of low-density lipoprotein receptor degradation. Recently, PCSK9 was shown to be overexpressed by liver cells in rats with proteinuria.
Huaying Shen, Sheng Feng, Ying Lu, Linsen Jiang, Tingting Yang, Zhi Wang   +5 more
doaj   +1 more source

SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. [PDF]

, 2013
The secretory pathway of eukaryotic cells packages cargo proteins into COPII-coated vesicles for transport from the endoplasmic reticulum (ER) to the Golgi.
Adams, Elizabeth, Bai, Yongsheng, Baines, Andrea, Bajaj, Kanika, Chen, Xiao-Wei, Ginsburg, David, Lin, Jiandie, Liu, Hui-Hui, Ma, Danjun, Meng, Zhuo-Xian, Sartor, Maureen A, Schekman, Randy, Wang, He, Yi, Zhengping, Young, Stephen G, Yu, Genggeng, Zhang, Bin, Zhang, Pengcheng   +17 more
core   +1 more source

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]

Journal of Lipid Research, 2015
Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact ...
Krista M. Schroeder, Thomas P. Beyer, Ryan J. Hansen, Bomie Han, Richard T. Pickard, Victor J. Wroblewski, Mark C. Kowala, Patrick I. Eacho   +7 more
doaj   +1 more source